The CY 2027 Medicare Advantage and Part D Final Rate Annoucement Has Landed: What Medicare Advantage Plans Must Do Now
Written by: Lesley Weir, CRC, Principal Solution Consultant, Veradigm
The waiting period is over
With the release of CMS’s CY 2027 Medicare Advantage and Part D Final Rate Announcement on April 6, 2026, health plans now have definitive clarity on the regulatory and financial conditions shaping the upcoming contract year. While CMS finalized a higher effective growth rate than originally proposed, the final rule confirms that performance in 2027 will depend less on benchmark growth and more on operational precision, data defensibility, and integration across risk, quality, and compliance functions.
The final rate announcement reinforces CMS’s broader strategy: tighten risk adjustment integrity, maintain aggressive audit oversight, and continue elevating the role of quality and Star Ratings—while preserving overall market stability. For plans, the direction is now set. Execution, not policy uncertainty, is the defining challenge.
Reality #1: Growth is higher—but margin pressure remains
CMS finalized an effective growth rate of 5.33%, contributing to a 2.48% net Medicare Advantage payment increase (approximately 4.98% when accounting for expected risk score trends). This represents a meaningful increase compared to the Advance Notice.
However, this topline growth is partially offset by downward pressure on risk scores driven by finalized risk adjustment policies, including diagnosis exclusions and normalization. As a result, growth alone will not expand margins.
To protect financial performance, plans should:
- Revalidate bid assumptions using final normalization factors
- Model the RAF impact of unlinked chart review and audioonly telehealth exclusions
- Perform Star Ratings sensitivity analysis to understand QBPdriven revenue shifts
- Identify administrative inefficiencies that inflate operating costs without improving compliance
Plans that tightly align finance, actuarial, and operational teams around finalized CMS mechanics will be best positioned to manage variability in 2027.
Reality #2: Risk adjustment defensibility is now nonnegotiable
CMS finalized the exclusion of diagnoses from unlinked chart review records (CRRs) beginning in CY 2027, citing data integrity concerns. Diagnoses submitted via retrospective chart review must now be supported by linkable encounters to count for risk adjustment.
CMS also finalized the exclusion of diagnoses captured solely through audioonly telehealth encounters, further reinforcing its expectations around encounterbased clinical documentation.
Limited exception: Beneficiaries who switch between MA organizations may still have unlinked CRR diagnoses counted. Beneficiaries moving from FFS Medicare into MA do not qualify.
For plans, this marks a structural shift:
- Retrospectiveheavy strategies face compression
- Prospective, encounteranchored capture becomes critical
- Data traceability is essential for both payment and audit defense
Risk adjustment must now be operationalized upstream—before submission and well before audit.
Reality #3: RADV exposure is permanent, not episodic
CMS continues to treat Risk Adjustment Data Validation (RADV) as a permanent oversight mechanism. Additional contract years are entering audit cycles, and CMS has reinforced expectations around documentation quality, submission timeliness, and traceability.
Audit readiness must be designed into daily operations:
- Centralized chart retrieval and submission governance
- Clear linkage between diagnosis, encounter, and clinical evidence
- Internal audits that mirror CMS sampling methodology
- Endtoend visibility from identification through defense
Plans that embed RADV preparedness into business as usual workflows significantly reduce downside risk.
Reality #4: Stars performance must be operationalized before the visit
CMS’s finalized 2027 policies continue to elevate the importance of clinical outcomes, member experience, and behavioral health performance. Star success is determined less by retrospective reporting and more by realtime workflow execution.
Highperforming plans:
- Surface HEDIS and Star gaps within the EHR
- Align scheduling and outreach to prioritize highimpact measures
- Ensure documentation specificity supports both quality and risk adjustment
- Coordinate member engagement for CAHPS and HOSdriven measures
Stars optimization is no longer a reporting function—it is a caredelivery discipline.
Reality #5: Administrative efficiency is the silent differentiator
Even with higher benchmark growth, rising operational complexity threatens margins. Fragmented workflows—manual chart retrieval, redundant vendors, siloed reporting—drive cost and delay execution.
CMS’s evolving expectations across risk adjustment, Stars, and RADV increase the importance of integrated operating models built on:
Identification → Activation → Validation → Submission → Defense
Administrative efficiency is no longer just cost control—it is a competitive advantage.
The closedloop imperative
The plans that succeed in 2027 will adopt a fully closedloop performance model that integrates risk, quality, finance, and compliance into a single execution framework.
This includes:
- Early identification of highvalue risk and quality gaps using encounteranchored data
- Provider and member activation embedded into workflows
- Structured validation prior to submission
- Unified, traceable data pipelines
- Auditready governance and oversight
Closing perspective
The CY 2027 Final Rate Announcement makes CMS’s expectations unmistakable:
- Accuracy is required
- Documentation must be defensible
- Quality must be operationalized
- Integration is essential
Plans that invest now in connected, endtoend infrastructure will do more than remain compliant—they will outperform their peers.
Veradigm partners with payers to build integrated performance systems designed for the realities of 2027 and beyond.